Merck KGaA (MKKGY) News Today $29.31 -0.41 (-1.38%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartDividendEarningsHeadlinesShort Interest All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Kepler Capital Sticks to Its Buy Rating for Merck KGaA (0O14)November 16, 2024 | markets.businessinsider.comMerck KGaA Third Quarter 2024 Earnings: Misses ExpectationsNovember 16, 2024 | finance.yahoo.comMerck initiated with a Peer Perform at Wolfe ResearchNovember 14, 2024 | markets.businessinsider.comMerck Snags Chinese Cancer Drug in Deal Worth Up to $3.3 BillionNovember 14, 2024 | msn.comMerck signs up to $3.3 billion cancer drug deal with China-based LaNovaNovember 14, 2024 | msn.comMerck KGaA stock falls on weak Q3, soft outlookNovember 14, 2024 | investing.comMerck KGaA (MKKGY) vs. Its Rivals Financial AnalysisNovember 11, 2024 | americanbankingnews.comMerck KGaA, Darmstadt, Germany and Intel Launch Academic Research Program in Europe for More Sustainable Semiconductor ManufacturingNovember 7, 2024 | financialpost.comMerck's Unity-SC acquisition bolsters optoelectronic capabilityNovember 4, 2024 | msn.comKepler Capital Reaffirms Their Buy Rating on Merck KGaA (0O14)November 3, 2024 | markets.businessinsider.comMerck Tops Earnings Estimates but Lowers Full-Year GuidanceNovember 2, 2024 | msn.comMerck price target lowered to $110 from $125 at Wells FargoNovember 1, 2024 | markets.businessinsider.comMerck Narrows Sales Outlook With Gardasil Lagging in ChinaNovember 1, 2024 | msn.comMerck cuts FY24 adjusted EPS view to $7.72-$7.77 from $7.94-$8.04November 1, 2024 | markets.businessinsider.comMerck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda ThreatOctober 25, 2024 | seekingalpha.comMerck price target lowered to $130 from $140 at CitiOctober 25, 2024 | markets.businessinsider.comMerck: EC approves two new indications for KeytrudaOctober 25, 2024 | markets.businessinsider.comMerck partners with Riley to provide free period products to four East Cork secondary schoolsOctober 24, 2024 | msn.comMerck buys cancer therapy developer Modifi Biosciences for up to $1.3 billionOctober 24, 2024 | msn.comMerck Keytruda cleared in EU for two new indications in gynecologic cancersOctober 24, 2024 | seekingalpha.comMerck antibody reduces RSV-related disease, hospitalizations in trialOctober 18, 2024 | finance.yahoo.comAI is driving semiconductor industry, says CEO Electronics at Merck KgaAOctober 18, 2024 | msn.comMerck's Posts More Positive Clesrovimab RSV Candidate Study DataOctober 17, 2024 | marketwatch.comGerman science and tech giant Merck confirms full-year guidanceOctober 17, 2024 | msn.comMerck lowers mid-term healthcare outlook after recent drug failuresOctober 17, 2024 | reuters.comMerck KGaA Shares Jump on Expectations of AI BoostOctober 17, 2024 | wsj.comMerck KGaA Trims Health Care And Life Sciences Targets, Eyes M&AOctober 17, 2024 | bloomberg.comMerck KGaA Cuts Medium-Term Healthcare, Life-Science Outlook but Lifts Electronics GuidanceOctober 17, 2024 | msn.comMerck Korea opens chip R&D center in GyeonggiOctober 10, 2024 | msn.comMerck opens spin-on-dielectric application lab for next-gen chipsOctober 10, 2024 | msn.comMerck unveils €290m biosafety testing facility in Maryland, USOctober 10, 2024 | finance.yahoo.comCerevance Achieves Second Milestone in Research Collaboration with MerckOctober 8, 2024 | finance.yahoo.comMerck immune from antitrust claim that it misled FDA about mumps vaccine, court rulesOctober 7, 2024 | reuters.comMerck: Murky Is A Better Description - Strong Sell (Technical Analysis)October 7, 2024 | seekingalpha.comEvaxion Biotech Gains Buy Rating Amid Merck Collaboration and AI-Driven Vaccine Development ProspectsSeptember 27, 2024 | markets.businessinsider.comMerck KGaA's (ETR:MRK) earnings growth rate lags the 11% CAGR delivered to shareholdersSeptember 27, 2024 | finance.yahoo.comMerck Reports Approval In Japan For KEYTRUDA Regimen For Certain Patients With NSCLCSeptember 26, 2024 | markets.businessinsider.comMerck Announces Expansion Of Nobivac NXT Platform For Treatment Of Feline Leukemia VirusSeptember 24, 2024 | markets.businessinsider.comMerck Gets European Panel Backing for Keytruda in Two Gynecologic CancersSeptember 20, 2024 | marketwatch.comMerck's Keytruda Secures First FDA-Approval For Rare Form Aggressive CancerSeptember 18, 2024 | benzinga.comMerck Gets First FDA Approval of Keytruda in Malignant Pleural MesotheliomaSeptember 18, 2024 | marketwatch.comMerck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage StudySeptember 17, 2024 | finance.yahoo.comMerck, Daiichi post late-stage trial win for novel lung cancer therapySeptember 17, 2024 | msn.comDaiichi Sankyo-Merck's cancer drug meets main goal in late-stage trialSeptember 17, 2024 | msn.comGilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravirSeptember 16, 2024 | finance.yahoo.comMerck : KEYTRUDA Combination Cuts Death Risk By 34% In Late-Stage Breast Cancer TrialSeptember 16, 2024 | markets.businessinsider.comMerck Scores Two Key Victories With Keytruda In Women's CancersSeptember 16, 2024 | msn.comMerck’s Top-Seller Cements Status in Hard-to-Treat Breast CancerSeptember 16, 2024 | bloomberg.comTen-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced MelanomaSeptember 15, 2024 | finance.yahoo.comMerck Keytruda cuts mortality risk by 33% in late-stage trial for cervical cancerSeptember 14, 2024 | seekingalpha.com Get Merck KGaA News Delivered to You Automatically Sign up to receive the latest news and ratings for MKKGY and its competitors with MarketBeat's FREE daily newsletter. Email Address My #1 Pre IPO Trade for 2025 – NAME and TICKER (Ad)One tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report... The Next SpaceX Pre-IPO MKKGY Media Mentions By Week MKKGY Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MKKGY News Sentiment▼-0.270.45▲Average Medical News Sentiment MKKGY News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MKKGY Articles This Week▼64▲MKKGY Articles Average Week Get Merck KGaA News Delivered to You Automatically Sign up to receive the latest news and ratings for MKKGY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies GSK News Today Takeda Pharmaceutical News Today UCB News Today Alnylam Pharmaceuticals News Today Teva Pharmaceutical Industries News Today BeiGene News Today Merck KGaA News Today Astellas Pharma News Today United Therapeutics News Today Viatris News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:MKKGY) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merck KGaA Please log in to your account or sign up in order to add this asset to your watchlist. Share Merck KGaA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MKKGY Stock Alerts